{"disease":{"id":"pruritus-in-progressive-familial-intrahepatic-cholestasis-pfic","name":"pruritus in progressive familial intrahepatic cholestasis pfic"},"drugs":{"marketed":[{"drug_id":"odevixibat","indication_name":"Pruritus in progressive familial intrahepatic cholestasis (PFIC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bylvay","generic_name":"ODEVIXIBAT","company_name":"Ipsen","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Bylvay works by blocking the ileal sodium/bile acid cotransporter, a protein that helps reabsorb bile acids in the intestines."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}